<DOC>
	<DOCNO>NCT01204658</DOCNO>
	<brief_summary>This study ass safety , reactogenicity immunogenicity two formulation GSK Biologicals ' pneumococcal vaccine 2189242A give 3-dose primary vaccination course first 6 month life follow booster dose 12-15 month age co-administered DTPa-HBV-IPV/Hib vaccine .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib Healthy Infants</brief_title>
	<detailed_description>This study ass safety , reactogenicity , immunogenicity persistence two formulation GSK Biologicals ' pneumococcal vaccine 2189242A [ high dose ( HD ) low dose ( LD ) ] give 3-dose primary vaccination course first 6 month life follow booster dose 12-15 month age co-administered Infanrix hexa™ compare vaccination Synflorix™ Prevnar 13™ similarly co-administered Infanrix hexa™ vaccine .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol Male female , include , 6 14 week ( 42104 day ) age time first vaccination . Written inform consent obtain parents/LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol study period start 30 day dose end 30 day dose vaccine ( ) , exception license flu vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination S. pneumoniae since birth . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect chronic illness . History neurologic disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature &gt; = 38.0°C rectal set &gt; = 37.5°C oral axillary setting . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/ blood product since birth plan administration primary epoch period start three month booster vaccination end one month booster vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>infant</keyword>
	<keyword>safety</keyword>
</DOC>